Jaguar Health's distribution is stock, not cash. Eligible holders must meet three key dates before each Series R preferred share converts into five common shares, as second-quarter revenue fell 71% short of analyst consensus.
On October 2, Jaguar Health's board declared Series R Convertible Preferred Stock for holders of voting common stock and certain warrants. The distribution is not a cash payment. Each preferred share is set to convert into five common shares.
To qualify, holders must own eligible shares at the close of business on October 13, 2026. The distribution is scheduled for October 15, and conversion is set for November 2. Jaguar's dividend announcement details set out those terms. Three dates matter.
The word "dividend" can mislead. Jaguar described the distribution as protection against potential dilution as it evaluates strategic alternatives and advances its crofelemer program. CEO Lisa Conte said the plan is intended to "reward and recognize" stockholders and "provide protection against potential dilution." The announcement does not describe a cash return. Eligible holders should treat the preferred-share distribution as distinct from a conventional dividend paid in dollars.
The company's second-quarter revenue was $1.23 million. MarketBeat's analyst consensus was $4.24 million, a shortfall of $3.01 million, or 71.0% based on those figures. That gap was wide. MarketBeat lists a Sell consensus based on one research report. Its earnings page also shows adjusted earnings per share of negative $15.70, compared with consensus of negative $782.25. Revenue is the more straightforward comparison in this update.
Between July 7 and September 14, 2026, Jaguar issued 304,473 common shares to retire 9.2 shares of Series Q Preferred Stock.
A separate dividend example shows the difference between stock and cash distributions. A cash dividend increases the payment shareholders receive. Jaguar's stated terms instead distribute convertible preferred shares. The label alone does not tell investors what they will receive or how the security will change.
JAGX closed at $3.66 on Nasdaq on October 2, down 7.34% from the prior session. The stock traded between $3.50 and $4.30 that day, with volume of 590,932 shares. The close was $1.31 above the 52-week low of $2.35 and 99.71% below the reported high of $1,267.88. This range is unusual. It is not a forecast of future performance.
Jaguar develops plant-derived prescription drugs for complicated gastrointestinal diseases. Its Napo Pharmaceuticals and Napo Therapeutics units are developing oral crofelemer for rare intestinal-failure conditions, including microvillus inclusion disease and short bowel syndrome. The company has said it is considering strategic alternatives and advancing drug-development work. The dividend announcement does not say which alternatives it may pursue or what outcome the program will produce.
A separate filing summary says a special stockholder meeting was scheduled for November 6, 2026. Proposals concern a reverse split and other capital-structure changes, as outlined in a preliminary proxy filing summary.
Investors should read this as a corporate-action timetable, not as evidence of cash income or a solution to Jaguar's revenue miss. A preferred share is a separate security, and its terms can include conversion into common stock. Here, each preferred share converts into five common shares on November 2. The record and distribution dates matter too. Revenue came in far below consensus, and the stock was near the bottom of its reported yearly range. The conversion terms are clear. They do not erase the operating shortfall.
